After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for ImmunityBio Inc. (IBRX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.60%, to $1.66. The ImmunityBio Inc. has recorded 5,103 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities.
IBRX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.67 and fluctuated between $1.8500 as its day high and $1.6200 as its day low. The current market capitalization of ImmunityBio Inc. is $715.41M. A total of 4.45 million shares were traded on the day, compared to an average of 2.67M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, IBRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 2 SELLs from insiders. Insiders purchased 10,211,416 shares during that period but sold 46,465.
In the most recent transaction, BLASZYK MICHAEL D bought 71,915 shares of IBRX for 2.75 per share on Jun 05. After the transaction, the Director now owns 71,915 company shares. In a previous transaction on Jun 02, Brennan John Owen bought 25,000 shares at 2.83 per share. IBRX shares that Director owns now total 25,000.
Among the insiders who bought shares, Clark Wesley acquired of 7,000 shares on Jun 01 at a per-share price of $2.91. This resulted in the Director holding 8,000 shares of IBRX after the transaction.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for IBRX in the last 3 months, the mean price target is $5.00 with high estimates of $5.00 and low estimates of $5.00. In terms of 52-week highs and lows, IBRX has a high of $7.10 and a low of $1.21.
As of this writing, IBRX has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.27. The company reported an EPS of -$0.27 in the last quarter, which was -22.70% lower than expectations of -$0.22.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. IBRX’s latest balance sheet shows that the firm has $317.12M in Cash & Short Term Investments as of fiscal 2021. There were $645.66M in debt and $369.00M in liabilities at the time. Its Book Value Per Share was -$1.47, while its Total Shareholder’s Equity was -$243.91M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IBRX is Buy with a score of 4.00.